Codexis
CDXS
Market cap $185M

2.23 USD

-0.02

0.89%

At close Jun 13, 4:00 PM EDT

After hours

2.20

-0.03

1.35%

1 day

-0.89%

5 days

-8.61%

1 month

-12.89%

3 months

-11.86%

6 months

-59.67%

Year to date

-55.40%

1 year

-28.98%

5 years

-79.86%

10 years

-45.61%

About: Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Employees: 188

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

138% more call options, than puts

Call options by funds: $38K | Put options by funds: $16K

25% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 40

0.44% less ownership

Funds ownership: 79.13% [Q4 2024] → 78.68% (-0.44%) [Q1 2025]

7% less funds holding

Funds holding: 135 [Q4 2024] → 126 (-9) [Q1 2025]

29% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 21

43% less capital invested

Capital invested by funds: $307M [Q4 2024] → $175M (-$132M) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CDXS.

See Analyst Rankings

Financial journalist opinion

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

Codexis to Participate in Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 3-5, 2025, in New York, New York.

Codexis to Participate in Jefferies Global Healthcare Conference

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

Codexis, Inc. (NASDAQ:CDXS ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Georgia Erbez - Chief Financial Officer Stefan Lutz - Senior Vice President of Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Tycho Peterson - Jefferies Allison Bratzel - Piper Sandler Dan Arias - Stifel Matthew Hewitt - Craig-Hallum Brendan Smith - TD Cowen Operator Greetings and welcome to the Codexis First Quarter 2025 Earnings Conference Call and webcast. At this time, all participants are in a listen-only mode.

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

Codexis (CDXS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

Codexis Reports First Quarter 2025 Financial Results

Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

Codexis Reports First Quarter 2025 Financial Results

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Codexis to Report First Quarter 2025 Financial Results on May 14

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

Codexis to Report First Quarter 2025 Financial Results on May 14

Zacks Investment Research

Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?

Codexis Announces Byron Dorgan to Retire from Board of Directors

REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company's Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board.

Codexis Announces Byron Dorgan to Retire from Board of Directors

Codexis Announces New Employment Inducement Grants

REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of Codexis common stock and (ii) 5,000 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.

Codexis Announces New Employment Inducement Grants

See News Rankings

Charts implemented using Lightweight Charts™